In the International stroke trial the group that received heparin had a significant 0.9% reduction in risk of recurrent stroke within 14 days. This was however counter balanced by a significant 0.8% increase in haemorrhagic stroke.
Trials involving low-molecular weight heparins, nadroparin and danaparoid have not convincingly shown benefit of these therapies.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page